• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

作者更正：细胞周期蛋白D - 细胞周期蛋白依赖性激酶4通过cullin 3 - SPOP使程序性死亡蛋白1配体（PD - L1）不稳定以控制癌症免疫监视。

Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.

作者信息

Zhang Jinfang, Bu Xia, Wang Haizhen, Zhu Yasheng, Geng Yan, Nihira Naoe Taira, Tan Yuyong, Ci Yanpeng, Wu Fei, Dai Xiangpeng, Guo Jianping, Huang Yu-Han, Fan Caoqi, Ren Shancheng, Sun Yinghao, Freeman Gordon J, Sicinski Piotr, Wei Wenyi

机构信息

Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

出版信息

Nature. 2019 Jul;571(7766):E10. doi: 10.1038/s41586-019-1351-8.

DOI:10.1038/s41586-019-1351-8
PMID:31270456
Abstract

An Amendment to this paper has been published and can be accessed via a link at the top of the paper. The original Letter has not been corrected.

摘要

本文的一个修订版本已发表，可通过本文顶部的链接获取。原始信件未作更正。

相似文献

1
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.作者更正：细胞周期蛋白D - 细胞周期蛋白依赖性激酶4通过cullin 3 - SPOP使程序性死亡蛋白1配体（PD - L1）不稳定以控制癌症免疫监视。
Nature. 2019 Jul;571(7766):E10. doi: 10.1038/s41586-019-1351-8.
2
Author Correction: Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors.作者更正：PD-1/PD-L1抑制剂治疗晚期非小细胞肺癌的真实世界证据及临床观察
Sci Rep. 2020 Jan 27;10(1):1525. doi: 10.1038/s41598-020-58487-5.
3
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.作者更正：高程序性死亡受体配体1（PD-L1）表达与晚期胆管癌患者对帕博利珠单抗的治疗反应相关。
Sci Rep. 2020 Dec 3;10(1):21552. doi: 10.1038/s41598-020-78512-x.
4
Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1.作者更正：细胞核程序性死亡配体1对姐妹染色单体黏连的调控
Cell Res. 2020 Sep;30(9):823. doi: 10.1038/s41422-020-0365-y.
5
Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.作者更正：乳腺癌细胞中药物诱导的PD-L1表达和细胞应激反应可通过联合用药实现平衡。
Sci Rep. 2020 Mar 5;10(1):4463. doi: 10.1038/s41598-020-60964-w.
6
Author Correction: PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.作者更正：PD-L1介导的gasdermin C表达使癌细胞中的凋亡转变为焦亡，并促进肿瘤坏死。
Nat Cell Biol. 2020 Nov;22(11):1396. doi: 10.1038/s41556-020-00599-1.
7
Author Correction: Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL.作者更正：表达程序性死亡受体配体1（PD-L1）的B细胞数量增加与艾滋病相关非霍奇金淋巴瘤（AIDS-NHL）的发生有关。
Sci Rep. 2020 Jan 15;10(1):748. doi: 10.1038/s41598-020-57442-8.
8
Correction: Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway.更正：巨噬细胞衍生的CCL5通过p65/STAT3-CSN5-PD-L1途径促进结肠癌细胞的免疫逃逸。
Cell Death Differ. 2020 Jul;27(7):2293. doi: 10.1038/s41418-020-0506-3.
9
Author Correction: Association of Cyclin Dependent Kinase 10 and Transcription Factor 2 during Human Corneal Epithelial Wound Healing in vitro model.作者更正：细胞周期蛋白依赖性激酶10与转录因子2在人角膜上皮体外伤口愈合模型中的关联
Sci Rep. 2020 Aug 27;10(1):14405. doi: 10.1038/s41598-020-71045-3.
10
Author Correction: ZFP36L1 and ZFP36L2 inhibit cell proliferation in a cyclin D-dependent and p53-independent manner.作者更正：ZFP36L1和ZFP36L2以细胞周期蛋白D依赖性和p53非依赖性方式抑制细胞增殖。
Sci Rep. 2019 Nov 20;9(1):17457. doi: 10.1038/s41598-019-53894-9.

引用本文的文献

1
MEN1 deficiency stabilizes PD-L1 and promotes tumor immune evasion of lung cancer.MEN1 缺失稳定了 PD-L1 并促进了肺癌的肿瘤免疫逃逸。
Cancer Sci. 2024 Aug;115(8):2515-2527. doi: 10.1111/cas.16196. Epub 2024 Apr 30.
2
TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.TMEM160 通过与 PD-L1 结合促进结直肠癌的肿瘤免疫逃逸和放疗抵抗。
Cell Commun Signal. 2024 Mar 7;22(1):168. doi: 10.1186/s12964-024-01541-w.
3
Targeting ATR in patients with cancer.针对癌症患者的 ATR 靶点治疗。
Nat Rev Clin Oncol. 2024 Apr;21(4):278-293. doi: 10.1038/s41571-024-00863-5. Epub 2024 Feb 20.
4
CDK4/6 inhibitors in lung cancer: current practice and future directions.CDK4/6 抑制剂在肺癌中的应用：现状与未来方向。
Eur Respir Rev. 2024 Feb 14;33(171). doi: 10.1183/16000617.0145-2023. Print 2024 Jan 31.
5
Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.PD-L1 翻译后修饰的调控与肿瘤免疫治疗的进展。
Front Immunol. 2023 Jul 24;14:1230135. doi: 10.3389/fimmu.2023.1230135. eCollection 2023.
6
Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape.肿瘤信号转导网络的支架蛋白：FK506 结合蛋白 51（FKBP51）支持肿瘤内在特性和免疫逃避的范例。
Oncol Res. 2023 Jun 27;31(4):423-436. doi: 10.32604/or.2023.028392. eCollection 2023.
7
A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.一种基于新型肿瘤突变负担的风险模型可预测卵巢癌的预后，并与免疫浸润相关。
Front Immunol. 2022 Aug 8;13:943389. doi: 10.3389/fimmu.2022.943389. eCollection 2022.
8
Tumor stem cell-derived exosomal microRNA-17-5p inhibits anti-tumor immunity in colorectal cancer via targeting SPOP and overexpressing PD-L1.肿瘤干细胞衍生的外泌体微小RNA-17-5p通过靶向SPOP并过表达PD-L1抑制结直肠癌的抗肿瘤免疫。
Cell Death Discov. 2022 Apr 23;8(1):223. doi: 10.1038/s41420-022-00919-4.
9
c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.c-Myb 通过 miR-145-5p/SPOP/PD-L1 轴促进食管腺癌细胞的免疫逃逸。
Clin Transl Med. 2021 Sep;11(9):e464. doi: 10.1002/ctm2.464.
10
PD-L1 Expression Fluctuates Concurrently with Cyclin D in Glioblastoma Cells.胶质母细胞瘤细胞中 PD-L1 表达与细胞周期蛋白 D 同步波动。
Cells. 2021 Sep 9;10(9):2366. doi: 10.3390/cells10092366.